Advanced Malignant NeoplasmSpritNCT01549067
The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey
An observational study of Advanced Malignant Neoplasm and Colorectal Cancer, run by Chinese Medical Doctor Association at 2 sites in China.
Trial summary
Collect the real clinical background of advanced colorectal cancer c of China. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Advanced Malignant Neoplasm, Colorectal Cancer
- How many people
- 3,700 participants
- Where
- 2 sitesChina
- Study dates
- Sep 2011to Dec 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Advanced Colorectal Cancer
Who may be able to join
- Patients with histologically or cytologically confirmed diagnosis of metastatic colorectal cancer.
Who cannot join
- Patients with histologically or cytologically confirmed diagnosis other than metastatic colorectal cancer.
Trial locations and contacts
2 sites in 1 country.
China2 sites, 2 recruiting
- Recruiting
Peking University Cancer Hospital
Beijing, Beijing Municipality
Lin Shen, MD, 010-88140650, lin100@medmail.com.cn
Lin Shen, MD
- Recruiting
Sun Yat-sen University Cancer Center
Zhongshan, Guangzhou
Rui-hua Xu, MD, PhD, 020-87343468, xurh@sysucc.org.cn
Rui-hua Xu, MD, PhD
About this study
Collect the real clinical background of advanced colorectal cancer c of China.
Read the detailed description
The Primary Objectives of this study is collect the real clinical background of advanced colorectal cancer treatment situation of China. The Secondary Objectives is the mutation of K-ras , targeting therapy , use present situation of cetuximab and liver metastases treatment situation of colorectal cancer patients.
- Conditions
- Advanced Malignant Neoplasm, Colorectal Cancer
- Keywords
- Advanced, Colorectal Cancer, Targeted chemotherapy, Surgery, Radiotherapy
- Medical subject headings
- Colorectal Neoplasms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Mar 2012 (estimated)
- Study startSep 2011
- Primary completionDec 2012 (estimated)
- Study completionDec 2012 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Malignant NeoplasmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Cross-sectional
- Enrolment
- 3,700 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese Medical Doctor Association
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lin Shen，MD & Ruihua Xu，MD、PhD, Chinese Medical Doctor Association
- Investigators
- Lin Shen, MD, Principal investigator, Peking University Cancer Hospital & InstituteRuihua Xu, MD, PhD, Principal investigator, Sun Yat-Sen University Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01549067
- Sponsor's protocol ID
- Sprit
- Acronym
- Sprit
- Status last verified
- Mar 2012
- First submitted
- 6 Mar 2012
- Last updated
- 14 Mar 2012
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Mar 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey
- ClinicalTrials.gov ID
- NCT01549067
- Acronym / sponsor ID
- Sprit / Sprit
- Conditions
- Advanced Malignant Neoplasm, Colorectal Cancer
- Keywords
- Advanced, Colorectal Cancer, Targeted chemotherapy, Surgery, Radiotherapy
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 3,700 participants (estimated)
- Lead sponsor
- Chinese Medical Doctor AssociationUniversity, hospital or other
- Study start
- Sep 2011
- Primary completion
- Dec 2012 (estimated)
- Study completion
- Dec 2012 (estimated)
- First posted
- 8 Mar 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Collect the real clinical background of advanced colorectal cancer c of China.
Detailed description
The Primary Objectives of this study is collect the real clinical background of advanced colorectal cancer treatment situation of China. The Secondary Objectives is the mutation of K-ras , targeting therapy , use present situation of cetuximab and liver metastases treatment situation of colorectal cancer patients.
Study design
- Time perspective
- Cross-sectional
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Advanced Colorectal Cancer
Key inclusion criteria (1 listed)
- Patients with histologically or cytologically confirmed diagnosis of metastatic colorectal cancer.
Key exclusion criteria (1 listed)
- Patients with histologically or cytologically confirmed diagnosis other than metastatic colorectal cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Mar 2012.
Related trials for Advanced Malignant Neoplasm
RecruitingPhase 1/2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 1/2
Phase 1/2 Study of DS010 in Advanced Cancer Patients With Cachexia
Cancer, Cachexia
Not yet recruitingPhase 1
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lin Shen, MD principal investigator
Peking University Cancer Hospital & Institute
Ruihua Xu, MD, PhD principal investigator
Sun Yat-Sen University Cancer Center
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Advanced Malignant Neoplasm and Colorectal Cancer, run by Chinese Medical Doctor Association at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Mar 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Lin Shen, MD (010-88140650, lin100@medmail.com.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2012.